Ivabradine Effects in Cardiogenic Shock Requiring Inotropic Support

The requested reference [ccf04e2c3ae4075c5e211982218f8e7e48414788] no longer exists in our database. It has been replaced by the current reference: [1ab91e828b29dd031ca74299f2aafb7584bdef63]

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2022
Data regarding the safety and efficacy of ivabradine use in severely decompensated HFrEF requiring inotropic support is limited to case series.1 This study aimed to evaluate ivabradine safety and tolerability in admitted cardiogenic shock patients who started on dobutamine infusion for inotropic support.
Epistemonikos ID: 5d6b08933b1c079c92caa7849577b6202eff1590
First added on: May 14, 2024